Alliance for mRNA Medicines
Become a Member

ParcelBio

David Weinberg

Co-Founder and CEO
ParcelBio
  • ParcelBio brings together deep expertise in RNA biology, CAR-T cell therapy, and drug development.
  • Backed by Breyer Capital, Y Combinator, General Catalyst, and top life science investors, ParcelBio is bringing a new class of mRNA medicines to patients.
  • The financing will support development of ParcelBio’s proprietary APEXm™ (Amplified and Prolonged EXpression mRNA) platform and advance its pipeline, including its lead in vivo CAR-T program for autoimmune disease, as well as additional programs in oncology and encoded protein therapeutics.
  • Current mRNA technologies are limited in their ability to achieve both high protein expression and sustained durability, so ParcelBio is developing a new category of mRNA medicines designed to overcome these limitations. Its proprietary APEXm™ platform engineers RNA molecules to actively recruit the cell’s native RNA-stabilizing machinery, enabling significantly higher and more durable protein expression. This approach leads to a step-change in biological performance, reaching therapeutic thresholds that have historically been out of reach for mRNA.